<link rel="stylesheet" href="styles.f3b1fba60ec7970c.css">

Infectious side effects of baricitinib: A big data analysis based on VigiBase

Simple item page
dc.authorid0000-0002-7919-1326
dc.authorid0000-0003-1555-4148
dc.authorid0000-0001-5784-726X
dc.authorid0000-0001-8022-7325
dc.contributor.authorMahroum, Naim
dc.contributor.authorÖzkan, Mehmet Fatih
dc.contributor.authorAbalı, Tunahan
dc.contributor.authorYılmaz, Mesut
dc.contributor.authorBragazzi, Nicola Luigi
dc.date.accessioned2023-01-06T08:26:40Z
dc.date.available2023-01-06T08:26:40Z
dc.date.issued2023
dc.departmentİstanbul Medipol Üniversitesi, Uluslararası Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalı
dc.description.abstractDear Editor, Baricitinib (known as “Olumiant”), is an inhibitor of Janus- associated kinase 1 and 2 (JAK1 and JAK2) initially introduced for the treatment of rheumatoid arthritis (RA), and later for systemic lupus erythematosus (SLE), and atopic dermatitis [1]. The first approval of baricitinib was from the European Medicines Agency (EMA) as a mon- otherapy or combination therapy with methotrexate for patients with RA unresponsive to disease-modifying anti-rheumatic drugs (DMARDs)
dc.identifier.citationMahroum, N., Özkan, M. F., Abalı, T., Yılmaz, M. ve Bragazzi, N. L. (2023). Infectious side effects of baricitinib: A big data analysis based on VigiBase. Autoimmunity Reviews, 22(1). https://dx.doi.org/10.1016/j.autrev.2022.103215
dc.identifier.doi10.1016/j.autrev.2022.103215
dc.identifier.issn1568-9972
dc.identifier.issn1873-0183
dc.identifier.issue1
dc.identifier.pmid36270598
dc.identifier.scopus2-s2.0-85144637273
dc.identifier.scopusqualityQ1
dc.identifier.urihttps://dx.doi.org/10.1016/j.autrev.2022.103215
dc.identifier.urihttps://hdl.handle.net/20.500.12511/10255
dc.identifier.volume22
dc.identifier.wos000911106400001en_US
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.institutionauthorMahroum, Naim
dc.institutionauthorÖzkan, Mehmet Fatih
dc.institutionauthorAbalı, Tunahan
dc.institutionauthorYılmaz, Mesut
dc.language.isoen
dc.publisherElsevier B.V.
dc.relation.ispartofAutoimmunity Reviewsen_US
dc.relation.publicationcategoryDiğer
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectBaricitinib
dc.subjectJAK Inhibitors
dc.subjectRheumatoid Arthritis
dc.subjectHerpes Zoster
dc.subjectOral Herpes
dc.titleInfectious side effects of baricitinib: A big data analysis based on VigiBase
dc.typeLetter

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
Mahroum-Naim-2023.pdf
Size:
606.17 KB
Format:
Adobe Portable Document Format
Description:
Tam Metin / Full Text
Download

License bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.44 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Diğer Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu